Regionalising Home-Based Treatment for Multiple Myeloma

Enhancing service provision through strategic collaboration

Traditional systemic anti-cancer therapy often requires frequent hospital visits, creating challenges for regional patients and health services. To improve access and reduce healthcare burden, Gippsland Regional Integrated Cancer Service partnered with local stakeholders to pilot a home-based self-administration model for bortezomib in eligible multiple myeloma patients.

The project aims to improve patient access by enabling subcutaneous self-administration at home, while also freeing up outpatient capacity. A comprehensive policy and patient education framework were developed, supported by oncology nurses, haematologists, and pharmacy teams. Patients are recruited during haematology appointments, trained by nurses, and supervised through their first cycle before transitioning to independent administration. Ongoing monitoring and support are provided, including access to the Symptom Urgent Review Service.

Implementation leverages existing systems to maintain safety and care quality. An evaluation will assess the model’s safety, feasibility, and impact through surveys and audits. The program may be scaled to other treatments and across the Gippsland region.

This innovative model offers a more accessible, patient-centred approach to cancer treatment in Gippsland, improving quality of life, care closer to home and optimising health system resources.